Economic issues with follow-on protein products

被引：31

作者：

Lanthier, Michael ^{[1
]}

Behrman, Rachel ^{[1
]}

Nardinelli, Clark ^{[1
]}

机构：

[1] US FDA, Rockville, MD 20857 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2008年 / 7卷 / 09期

关键词：

D O I：

10.1038/nrd2636

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The economic effects of the possible introduction of 'follow-on' protein products have been the subject of recent debate. Here, we aim to explore the economic issues surrounding this debate using three measures: total sales, product complexity and patent expiry. Our analysis shows that the sales of therapeutic protein products are concentrated in a relatively small number of branded products, which may be the most attractive targets for follow- on development. For the years 2013-2015, we estimate that products representing US$ 20 billion in annual sales-approximately half of all sales in 2006-can be expected to lose patent protection.

引用

页码：733 / 737

页数：5

共 12 条

[1] What's fueling the biotech engine? [J].